Cellectis SA/ US15117K1034 /
2024-08-28 9:57:53 PM | Chg. -0.0100 | Volume | Bid10:02:59 PM | Ask10:02:59 PM | High | Low |
---|---|---|---|---|---|---|
2.3700USD | -0.42% | 32,450 Turnover: 73,432.4488 |
1.8700Bid Size: 1,500 | 2.4300Ask Size: 100 | 2.4250 | 2.3501 |
GlobeNewswire
08-08
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First...
GlobeNewswire
08-07
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
GlobeNewswire
08-01
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
GlobeNewswire
07-25
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product c...
GlobeNewswire
07-16
Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as D...
GlobeNewswire
07-01
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase ...
GlobeNewswire
06-20
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
GlobeNewswire
06-20
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cem...
GlobeNewswire
06-12
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
GlobeNewswire
06-04
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients wi...
GlobeNewswire
05-13
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
GlobeNewswire
05-09
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
GlobeNewswire
05-06
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
GlobeNewswire
04-26
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advan...
GlobeNewswire
04-22
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene...